Skip to content

Lantheus Holdings LNTH Weighted Average Exercise Price of Vested and Expected to Vest Options

Weighted Average Exercise Price of Vested and Expected to Vest Options at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$377.3M+1.2%
Gross profit$230.9M-2.9%
Operating income$81.3M-20.3%
Net income$118.4M+62.3%
EPS (diluted)$1.80+76.5%

Balance sheet

See full
Cash & equivalents$500.3M-46.8%
Total debt$627.9M+1.8%
Total equity$1.2B+4.1%
Total assets$2.3B+14.2%

Cash flow

See full
Operating cash flow$125.1M+16.3%
CapEx$3.2M-63.0%
Free cash flow$121.9M+23.3%

Valuation

See full
Market cap$6.76B-26.3%
Enterprise value$6.89B-20.5%
P/E24.2×-10.2×
P/S4.4×-1.6×

Profitability

See full
Gross margin60.5%-3.6pp
Operating margin18.8%-10.7pp
Net margin18%+0.7pp
FCF margin24.4%-6.4pp

Returns & leverage

See full
Return on equity23.5%-1.7pp
Debt / equity0.5×0.0×
Current ratio2.8×-2.9×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice.

The official record: Lantheus Holdings’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lantheus Holdings's weighted average exercise price of vested and expected to vest options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lantheus Holdings's weighted average exercise price of vested and expected to vest options?
Lantheus Holdings (LNTH) reported weighted average exercise price of vested and expected to vest options of $69.07 in Q4 2025.
What does weighted average exercise price of vested and expected to vest options mean?
This metric represents the average price at which holders of vested and expected-to-vest stock options can purchase company shares. It serves as a key indicator of the potential dilution cost and the alignment between employee incentives and shareholder value. Investors use this to assess the 'in-the-money' status of outstanding equity compensation.